The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026. This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — comparing baricitinib at 2 mg and 4 mg daily against TNF inhibitors (etanercept or adalimumab) in RA patients specifically enriched for venous thromboembolic event risk factors.
Dr. John Cush RheumNow
3 months 1 week ago
CAR-T Topic Panel: EULAR 2026
Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T, from emerging data and treatment strategies to real-world challenges in diagnosis and management.
https://t.co/cEOgxNYOXP https://t.co/EUpY9CLL6A
Dr. John Cush RheumNow
3 months 1 week ago
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/j2jrBIiuOo
Dr. John Cush RheumNow
3 months 1 week ago
Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B
As EULAR2026 comes to a close, practical learnings take precedence as clinicians head back to their clinics. Among them, the 2026 EULAR Update on Imaging Recommendations in SpA stands out.
Dr. John Cush RheumNow
3 months 1 week ago
True or False: Current guidelines for peripheral SpA recommend initiating treatment with TNF inhibitors before trying NSAIDs or conventional synthetic DMARDs. See if you got it right in this week's RheumIQ quiz at https://t.co/6uiqJjYUVo https://t.co/9hHFjaGUdt
Dr. John Cush RheumNow
3 months 1 week ago
“Science is organized knowledge. Wisdom is organized life.” - Immanuel Kant
Dr. John Cush RheumNow
3 months 1 week ago
LLMs in SLE: From Patient Education to Clinical Decision Support
The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical https://t.co/0rhada36Ji
Dr. John Cush RheumNow
3 months 1 week ago
NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.
https://t.co/8eZyDxL7wu https://t.co/Nvbj1NQb5A
The EULAR 2026 Congress in London showcased growing interest in T-cell engagers as a novel strategy to achieve deep B-cell depletion and drug-free remission in refractory rheumatic and musculoskeletal diseases (RMDs).
